JP2012525398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525398A5 JP2012525398A5 JP2012508607A JP2012508607A JP2012525398A5 JP 2012525398 A5 JP2012525398 A5 JP 2012525398A5 JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012508607 A JP2012508607 A JP 2012508607A JP 2012525398 A5 JP2012525398 A5 JP 2012525398A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ophthalmic
- tocotrienol
- alpha
- vision
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 117
- 208000035475 disorder Diseases 0.000 claims description 100
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 80
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 80
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 80
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 74
- 201000004569 Blindness Diseases 0.000 claims description 71
- 238000009472 formulation Methods 0.000 claims description 71
- 230000004393 visual impairment Effects 0.000 claims description 71
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 60
- 239000011730 α-tocotrienol Substances 0.000 claims description 60
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 60
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 56
- 208000018769 loss of vision Diseases 0.000 claims description 36
- 231100000864 loss of vision Toxicity 0.000 claims description 36
- 230000000750 progressive effect Effects 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 35
- 150000002148 esters Chemical class 0.000 claims description 34
- 208000014674 injury Diseases 0.000 claims description 34
- 208000002780 macular degeneration Diseases 0.000 claims description 34
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 32
- 230000007812 deficiency Effects 0.000 claims description 30
- 208000011580 syndromic disease Diseases 0.000 claims description 30
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 28
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 28
- 230000001684 chronic effect Effects 0.000 claims description 28
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 28
- 208000018737 Parkinson disease Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 229930003802 tocotrienol Natural products 0.000 claims description 25
- 239000011731 tocotrienol Substances 0.000 claims description 25
- 235000019148 tocotrienols Nutrition 0.000 claims description 25
- 102000014461 Ataxins Human genes 0.000 claims description 24
- 108010078286 Ataxins Proteins 0.000 claims description 24
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 24
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 24
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 24
- 208000012268 mitochondrial disease Diseases 0.000 claims description 24
- 230000008733 trauma Effects 0.000 claims description 24
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 23
- 208000014644 Brain disease Diseases 0.000 claims description 22
- 208000032274 Encephalopathy Diseases 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 22
- 208000017442 Retinal disease Diseases 0.000 claims description 20
- 230000004770 neurodegeneration Effects 0.000 claims description 19
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 19
- 208000010412 Glaucoma Diseases 0.000 claims description 18
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 18
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 18
- 230000000699 topical effect Effects 0.000 claims description 17
- 208000027073 Stargardt disease Diseases 0.000 claims description 16
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 16
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 15
- 206010033799 Paralysis Diseases 0.000 claims description 15
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 15
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 14
- 208000030768 Optic nerve injury Diseases 0.000 claims description 14
- 206010038923 Retinopathy Diseases 0.000 claims description 14
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 14
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 14
- 239000011722 γ-tocotrienol Substances 0.000 claims description 14
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 14
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 14
- 239000011729 δ-tocotrienol Substances 0.000 claims description 14
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 14
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 14
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 13
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 13
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 13
- 239000011723 β-tocotrienol Substances 0.000 claims description 13
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 13
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 13
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 12
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 12
- 239000003732 agents acting on the eye Substances 0.000 claims description 12
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 12
- 208000006443 lactic acidosis Diseases 0.000 claims description 12
- 229940125702 ophthalmic agent Drugs 0.000 claims description 12
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 10
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 10
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 10
- 208000028226 Krabbe disease Diseases 0.000 claims description 10
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 10
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 10
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 10
- 206010030113 Oedema Diseases 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 208000001749 optic atrophy Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 230000000642 iatrogenic effect Effects 0.000 claims description 7
- 238000002647 laser therapy Methods 0.000 claims description 7
- 238000002428 photodynamic therapy Methods 0.000 claims description 7
- 238000011476 stem cell transplantation Methods 0.000 claims description 7
- 102000007371 Ataxin-3 Human genes 0.000 claims description 6
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 6
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 6
- 206010057410 Hippus Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000006136 Leigh Disease Diseases 0.000 claims description 6
- 208000017507 Leigh syndrome Diseases 0.000 claims description 6
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 6
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- -1 alpha-tocotrienol ester Chemical class 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 208000035965 Postoperative Complications Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
- 229940113601 irrigation solution Drugs 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 3
- 150000003612 tocotrienol derivatives Polymers 0.000 claims description 2
- 150000003773 α-tocotrienols Polymers 0.000 claims description 2
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 26
- 238000002560 therapeutic procedure Methods 0.000 claims 13
- 229940012356 eye drops Drugs 0.000 claims 3
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 230000002262 irrigation Effects 0.000 claims 2
- 238000003973 irrigation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 210000003205 muscle Anatomy 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 208000021090 palsy Diseases 0.000 description 9
- 208000032253 retinal ischemia Diseases 0.000 description 4
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21476009P | 2009-04-28 | 2009-04-28 | |
| US61/214,760 | 2009-04-28 | ||
| PCT/US2010/032622 WO2010126910A1 (en) | 2009-04-28 | 2010-04-27 | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525398A JP2012525398A (ja) | 2012-10-22 |
| JP2012525398A5 true JP2012525398A5 (enExample) | 2013-06-13 |
Family
ID=43032521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508607A Pending JP2012525398A (ja) | 2009-04-28 | 2010-04-27 | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120136048A1 (enExample) |
| EP (1) | EP2424360A4 (enExample) |
| JP (1) | JP2012525398A (enExample) |
| BR (1) | BRPI1015006A2 (enExample) |
| CA (1) | CA2760357A1 (enExample) |
| WO (1) | WO2010126910A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583084C (en) | 2003-09-19 | 2010-12-07 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| EP2564842A1 (en) * | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| CA2704473C (en) | 2007-11-06 | 2016-10-04 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2974482C (en) | 2008-10-28 | 2019-10-29 | Bioelectron Technology Corporation | High purity alpha tocotrienol quinone and processes for preparing same |
| NO2424495T3 (enExample) | 2009-04-28 | 2018-06-16 | ||
| SI2470168T1 (en) * | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| WO2012158018A2 (en) * | 2011-05-18 | 2012-11-22 | Malaysian Palm Oil Board | Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to angiogenesis and method of preparation thereof |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| CN114702406B (zh) | 2014-12-16 | 2025-02-25 | Ptc医疗公司 | 化合物的多晶型和无定形形式 |
| EP3390377A1 (en) | 2015-12-16 | 2018-10-24 | BioElectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| AU2016369616B2 (en) | 2015-12-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018136871A1 (en) * | 2017-01-20 | 2018-07-26 | Ohio State Innovation Foundation | Topical tocotrienol compositions and methods of increasing skin stem cells |
| MY210324A (en) | 2018-10-17 | 2025-09-11 | Ptc Therapeutics Inc | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING a-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
| EP3981397A1 (en) * | 2020-10-08 | 2022-04-13 | Global Scientific | Tocotrienols derivates, methods and uses thereof |
| MX2024000445A (es) | 2021-07-08 | 2024-04-05 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilc iclohexa-2,5-dieno-1,4-diona. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217992A (en) * | 1989-10-04 | 1993-06-08 | Bristol-Myers Squibb Company | Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders |
| JPH09157165A (ja) * | 1995-12-11 | 1997-06-17 | Lion Corp | 点眼薬及び白内障の遅延・治療用剤 |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JP4447198B2 (ja) * | 2001-02-08 | 2010-04-07 | 富士化学工業株式会社 | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
| US20040034093A1 (en) * | 2002-05-30 | 2004-02-19 | Hensley Kenneth L. | Methods for enhancing motor performance and/or endurance |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| CA2583084C (en) * | 2003-09-19 | 2010-12-07 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| ES2532997T3 (es) * | 2005-04-22 | 2015-04-06 | Elizabeth Stuart | Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia |
| US20070092502A1 (en) * | 2005-09-01 | 2007-04-26 | Allergan, Inc. | Method of Treating Glaucoma |
| JP5374162B2 (ja) * | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| JP5731980B2 (ja) * | 2008-10-09 | 2015-06-10 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
-
2010
- 2010-04-27 JP JP2012508607A patent/JP2012525398A/ja active Pending
- 2010-04-27 US US13/266,240 patent/US20120136048A1/en not_active Abandoned
- 2010-04-27 EP EP10770214A patent/EP2424360A4/en not_active Withdrawn
- 2010-04-27 WO PCT/US2010/032622 patent/WO2010126910A1/en not_active Ceased
- 2010-04-27 BR BRPI1015006A patent/BRPI1015006A2/pt not_active IP Right Cessation
- 2010-04-27 CA CA2760357A patent/CA2760357A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525398A5 (enExample) | ||
| JP2012525397A5 (enExample) | ||
| Aragona et al. | Modern approach to the treatment of dry eye, a complex multifactorial disease: a PICASSO board review | |
| US20120136048A1 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
| DE69423782T2 (de) | Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck | |
| CN102811610B (zh) | 无刺激性眼科聚维酮碘组合物 | |
| JP5959507B2 (ja) | 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン | |
| JP2016128523A (ja) | 眼科疾患を治療するためのトコトリエノールキノンの製剤 | |
| SI2424495T1 (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| JP2012525399A5 (enExample) | ||
| AU2011274245B2 (en) | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease | |
| JP2023179418A (ja) | 近視の進行を制御し且つ／又は減少させるための医薬組成物 | |
| US20180243209A1 (en) | Use of selected anticholinergic zwitterions | |
| WO2018074421A1 (ja) | 眼科用剤及び眼科用薬 | |
| JP2009519962A5 (enExample) | ||
| Qamar et al. | Supratarsal injection of triamcinolone for vernal keratoconjunctivitis | |
| CN116350790B (zh) | 组合物及其在制备用于治疗老花眼的药物中的用途 | |
| Guan et al. | Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models | |
| KR20110025824A (ko) | 조절성 눈피로의 예방 또는 치료용 화합물 | |
| Nowroozzadeh | Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis | |
| Song et al. | The role of lipid metabolism disorder in the progression and treatment of ocular vascular diseases | |
| Apel | A child with itchy eyes | |
| WO2017075019A1 (en) | Eye drops | |
| US20170165226A1 (en) | Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis | |
| IT202100005777A1 (it) | Composizione per l’uso nel trattamento dell’occhio secco |